Australia's most trusted
source of pharma news
Thursday, 29 January 2026
Posted 29 January 2026 AM
Roche's goal of being a top three player in the obesity market is on track following strong results in a Phase 2 trial for its prime candidate.
The pharma announced topline results of a Phase 2 trial of CT-388 in treating obesity, an investigational dual GLP-1/GIP receptor agonist it obtained when it bought Carmot Therapeutics in 2023.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.